Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PharmAsia News India Pharma Roundup: Glenmark, FMRAI, Synchron/Parexel, Suven Life Sciences, Merck/Ranbaxy/Teva/Credit Suisse

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Mumbai-based Glenmark Pharmaceuticals has split its corporate structure into speciality and generic units to better manage the "diverse businesses that had both attained a critical mass.

You may also be interested in...



Glenmark Continues Search For New Partners As Merck Diabetes Agreement Ends, Reports Strong Q4 Earnings

MUMBAI - Glenmark Phamaceuticals said it is continuing to seek partners to develop its DPP-IV inhibitor melogliptin for type 2 diabetes treatment through outlicensing after it ended an agreement with Merck Serono to develop the drug

Glenmark Continues Search For New Partners As Merck Diabetes Agreement Ends, Reports Strong Q4 Earnings

MUMBAI - Glenmark Phamaceuticals said it is continuing to seek partners to develop its DPP-IV inhibitor melogliptin for type 2 diabetes treatment through outlicensing after it ended an agreement with Merck Serono to develop the drug

Ranbaxy Will Begin U.S. Sales Of Generic Nexium In 2014 Under Deal Ending Patent Litigation

Related Content

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel